Company intelligence / Profile preview
Medicure Inc.
Winnipeg, Manitoba, Canadamedicure.com ↗
- Ownership
- Private
- Employees
- ~38
- Development stage
- Phase 3
01
Overview
Medicure has commercial products AGGRASTAT (tirofiban hydrochloride) and ZYPITAMAG (pitavastatin). The company is also in Phase 3 clinical trials for MC-1 for the treatment of seizures associated with PNPO deficiency, which has received Fast Track designation, Rare Pediatric Disease Designation, and Orphan Drug Designation from the FDA.
- Therapeutic areas
- Rare DiseasesCardiovascular
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Zydus Cadila (for ZYPITAMAG)
Beyond the preview
Go deeper on Medicure Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Medicure Inc..